1239P ORCHARD osimertinib + savolitinib interim analysis: A biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib

Helena A. Yu, Xiuning Le, Christina S. Baik et al.|Annals of Oncology|2021

Cited by 47